Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | FABP7 | O15540 | 1/20 | 0.33 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4672613 | 0.85 | HTT (0.50) | HTTALDH1A1HSD17B10MEN1TSHR | |
| SCHEMBL1143909 | 0.84 | HTT (0.59) | HTTALDH1A1HSD17B10MEN1TSHR | |
| SCHEMBL14281229 | 0.81 | HTT (0.32) | HTTGLO1 | |
| SCHEMBL36595 | 0.81 | TSHR (0.48) | HTTALDH1A1HSD17B10MEN1TSHR | |
| SCHEMBL28031899 | 0.81 | TSHR (0.48) | HTTALDH1A1HSD17B10MEN1TSHR | |
| SCHEMBL19796057 | 0.81 | HTT (0.46) | HTTALDH1A1HSD17B10MEN1TSHR | |
| SCHEMBL3795624 | 0.79 | HTT (0.45) | HTTALDH1A1HSD17B10MEN1TSHR | |
| Fluoride SCHEMBL28255897 | 0.79 | TSHR (0.47) | HTTALDH1A1HSD17B10MEN1TSHR | |
| SCHEMBL333504 | 0.79 | — | — | |
| SCHEMBL15369326 | 0.78 | HTT (0.48) | HTTALDH1A1HSD17B10MEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114524777-B | Synthesis method of dihydro-oxazole compound | 南京先进生物材料与过程装备研究院有限公司 | 2023-10-10 | — | — | CN | claimed |
| CN-114524777-B | Synthesis method of dihydro-oxazole compound | 南京先进生物材料与过程装备研究院有限公司 | 2023-10-10 | — | — | CN | disclosed |
| US-20220123241-A1 | PREPARATION AND LAYER | NeuDrive Llimited (GB) | 2022-04-21 | — | — | US | disclosed |
| EP-3464252-B1 | FLUOROCHEMICAL PIPERAZINE CARBOXAMIDES | 3M INNOVATIVE PROPERTIES CO (US) | 2020-03-25 | — | — | EP | disclosed |
| US-10578969-B2 | Photoresist topcoat compositions and methods of processing photoresist compositions | ROHM AND HAAS ELECTRONIC MATERIALS LLC (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190235385-A1 | PHOTORESIST TOPCOAT COMPOSITIONS AND METHODS OF PROCESSING PHOTORESIST COMPOSITIONS | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT | 2019-08-01 | — | — | US | disclosed |
| CN-101124220-B | 5-substituted quinoline and isoquinoline derivatives, process for their preparation and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AG | 2012-04-25 | — | — | CN | disclosed |
| US-7417056-B2 | 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | SCHERING AG (DE) | 2008-08-26 | — | — | US | disclosed |
| CN-101124220-A | 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | SCHERING AG (DE) | 2008-02-13 | — | — | CN | disclosed |
| US-20060116396-A1 | 5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116396-A1 | 5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | NFKBIA, PTGS2, PTGES2 | HTT 3447/4885ALDH1A1 760/4885HSD17B10 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.